Prevalence and diversity of ciprofloxacin-resistant Klebsiella pneumoniae clinical isolates

The persistence and proliferation of multidrug-resistant microorganisms have the potential to occur in health centers and patient care units. WHO reports that cases of Klebsiella pneumoniae infection treated with ciprofloxacin in 34 countries have resistance from 4.1% to 79.4%. This study aimed to analyze the prevalence and diversity of ciprofloxacin-resistant K. pneumoniae from patients at Margono Soekardjo Hospital, Purwokerto. This study used a purposive sampling technique from blood, sputum, urine, pus, feces, and pleural fluid. The research process includes isolates characterization and identification, ciprofloxacin resistance testing, and its prevalence. This study recorded 99 cases of K. pneumoniae infection, and 48.5% of isolates were resistant to ciprofloxacin from August-September 2022. Biochemical and morphological tests showed a characteristic diversity of isolated K. pneumoniae against K. pneumoniae subspecies pneumoniae. The prevalence of ciprofloxacin-resistant K. pneumoniae was from blood (7.1%), sputum (59.6%), pus (23.2%), urine (6.1%), feces (3.03%), and pleural fluid (1.01%).